Get to know our clinical trials
Clinical trial of Dato-DXd, with or without osimertinib, versus platinum derivative chemotherapy in participants with locally advanced or metastatic EGFR-mutated non-small cell lung cancer
THE OBJECTIVE OF THIS STUDY IS TO EVALUATE WHETHER DATO-DXD ALONE (MONOTHERAPY), OR IN COMBINATION WITH OSIMERTINIB, CAN SAFELY ALLOW LONGER DISEASE CONTROL COMPARED TO THE CURRENT GOLD STANDARD TREATMENT (GT) OPTION OF CHEMOTHERAPY IN PATIENTS WHO HAVE FAILED PRIOR OSIMERTINIB TREATMENT.
Technical Summary
- PHASE III, RANDOMIZED, OPEN-LABEL, PROMOTER-MASKED, PHASE III STUDY OF DATO-DXD, WITH OR WITHOUT OSIMERTINIB, VERSUS PLATINUM DERIVATIVE BI-CHEMOTHERAPY IN PARTICIPANTS WITH EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS PROGRESSED ON PRIOR OSIMERTINIB TREATMENT (TROPION-LUNG15).
- Code EudraCT: 2024-511362-37
- Protocol number: D516KC00001
- Promoter: Astra Zeneca AB
- Molecule/Drug: Dato-DXd solo en combinación con osimertinib
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.